Tóm tắt

The textbook aims to be valued by different groups of reader. Its core purpose is still to provide a foundation from understanding the science to clinical training in undergraduate medicine. In addition, the content here should also be invaluable for postgraduate clinicians training in the specialty of endocrinology and diabetes. Written 'exit' examinations have become increasingly common during the later stages of clinical specialty training and we hope our textbook provides complementary study material alongside larger reference textbooks and published clinical guidelines. From feedback, we realise that our book has been valued by biomedical undergraduate and masters students and by those pursuing clinical biochemistry. We hope the new content increases this reach across different audiences. Learning objectives, recap points, cross-referencing guides, boxes, and concluding key points help orientate the reader and emphasize the major topics. Based on the success of previous editions, the book is still structured in much the same way. The first part is designed to create a knowledgeable reader, well prepared for the clinical sections or for more specific scientific study. To assist the many students coming from non-scientific backgrounds we limit assumptions on prior knowledge. Chapter 1 still covers the core principle of feedback regulation which underlies nearly all endocrine physiology and is vital for the correct interpretation of many clinical tests. Chapter 3 has advanced to encompass the latest research made possible from next generation sequencing technology. The latter has already started to impact significantly on clinical investigation and diagnostics in endocrinology and diabetes. This is covered in Chapter 4, which also includes positron emission tomography (PET) imaging. It is important that aspiring clinicians, as well as scientists, appreciate these new approaches, their application and their challenges. The second part of the book still follows its organ or system-based approach. We have retained the more specific scientific knowledge at the start of these chapters to underpin understanding, diagnosing and managing the relevant clinical disorders. The third part on diabetes and obesity has seen the greatest change from the previous edition. Over the last 8 years, there have been significant advances in the treatment of both type 2 diabetes, such as the new incretin-based therapies and SGLT2 inhibitors, and type 1 diabetes with the development of better insulins and the use of technology to support self-management. Clinical algorithms have also changed and these have been updated-- $c Provided by publisher.